Scapho contains Secukinumab, a monoclonal antibody used to treat autoimmune inflammatory conditions. It works by targeting interleukin-17A (IL-17A), a protein that causes inflammation in diseases like psoriasis, psoriatic arthritis, and ankylosing spondylitis. By inhibiting IL-17A, Scapho helps reduce inflammation, pain, and skin lesions.

Mechanism of action:
Secukinumab binds to IL-17A, preventing it from activating its receptors on cells. IL-17A is a key driver of inflammation, skin cell overgrowth, and joint damage. Blocking this protein reduces immune system overactivity, leading to improvement in skin symptoms, joint pain, and swelling.

Uses:

• Plaque psoriasis in adults

• Psoriatic arthritis

• Ankylosing spondylitis

• Helps reduce inflammation, improve mobility, and clear skin lesions

Adverse effects:
Common side effects include upper respiratory infections, headache, diarrhea, and injection site reactions. Rare but serious side effects include serious infections, allergic reactions, or inflammatory bowel disease flare-ups. Patients are often screened for tuberculosis and other infections before starting treatment.